



Ensuring better outcomes for lung cancer patients

PhD workshop, Health, Aarhus University, January 2024

Rasmus Thomsen, Health System Partner


Nov.23 | external



Agenda

- 1. Introduction to case provider
- 2. Why solve for lung cancer
- 3. Our ambition
- 4. What are we already doing
- 5. The case challenge





100,920 Employees worldwide Marketing and distribution **29,395**

Manufacturing and logistics 19,309

Services

16,124

Research and development

22,746

General and administration


6,160




Why Lung Cancer?

Global Burden of disease is on the rise

Lung cancer is one of the most common cancers worldwide and the leading cause of cancer-related deaths in 2020.






Reference: Globocan 5



Why Lung Cancer?

Global Burden of disease is on the rise



Lung cancer remains the leading cause of cancer deaths in Denmark



Denmark had 5,047 new cases and 3,927 deaths in 2020

55,6% of patients are diagnosed at stage IIIB-IV

These patients have a 5-year survival rate of **5.8%**

With early diagnosis, the 5-year survival rate increases to 59%

Early diagnosis could extend the lifespan of 4.000 people each year



10 major pain points

Social inequality determines behavior Difficult to see early symptoms **Patients** 3 High risk patients do not visit doctor High risk patients ignore symptoms 4 5 GPs are not well versed in lung cancer Primary sector 6 Delay in referral to tests & scans Regional differences System 8 No easy access to tests & CT scans Lack of radiologists Capacity 10 Delay in diagnosis



Roche Denmark 10-year ambition

We will pioneer preventive and personalized solutions to deliver twice as many medical advances at half the cost to society and double access to novel, high-medical-value diagnostics solutions.

Nobody should be diagnosed with stage IIIb-IV lung cancer



Our ambition

We will bend the mortality curve for lung cancer patients by ensuring that 60%* of patients are diagnosed in stage I-II by 2030





The case challenge

We are looking for a solution that can enhance the early detection and prevention of lung cancer.

Not a new medical treatment or medical device.

It can be a service solution, a new technology or a new preventive tool, e.g. the right biomarkers or a blood based screening test to enhance early detection, or perhaps a sophisticated screening tool that identifies high-risk population.

Maybe even a new preventive tool that also adjusts for social inequality?



The team may focus on one of these challenges

Better use of technology

How could we enable early diagnosis for all lung cancer patients, and change the patient journey? E.g. By use of Al and big data.

Tools and measurers

What kind of tools would be useful in a screening and prevention program, and


Which initiatives/tools could be used to target the risk group

What are the right interventions?

What are the right interventions needed to create more equality in the treatment of lung cancer? E.g. targeted at the following areas; lifestyle both before, during, and after treatment, faster assessments, navigation in the health system, optimization of comorbidity during and after treatment.



We need a holistic approach



If we focus in one area, we potentially create problems in other areas






And we need new perspectives if we are to find a sustainable solution that will move the needle





And it starts with awareness and bringing in talents of the future with the right mindset









Doing now what patients need next